LAG-3 expression in tumor microenvironment of triple-negative breast cancer

Akyurek, Nalan; tahtaci, gozde; GÜNEL, NAZAN; Sadioğlu, Aysu; Boz, Oğulcan

doi:10.55730/1300-0144.5567

LAG-3 expression in tumor microenvironment of triple-negative breast cancer

gozde tahtaci, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Nazan GÜNEL, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Aysu SADİOĞLU, (Gazi Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Nalan AKYÜREK, (Gazi Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Oğulcan BOZ (Gazi Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Medical Sciences

1 1

Yıl: 2023 Cilt: 53 Sayı: 1 Sayfa Aralığı: 142 - 148 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5567 İndeks Tarihi: 24-03-2023

LAG-3 expression in tumor microenvironment of triple-negative breast cancer

Öz:

Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman’s correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. Results: The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15–2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56–13.02) (p = 0.215), respectively). Conclusion: High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.

Anahtar Kelime: Breast cancer LAG-3 PD-L1 tumor infiltrating lymphocytes triple-negative

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. CA: A Cancer Journal for Clinicians 2021; 71 (1): 7-33. https://doi. org/10.3322/caac.21654
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 2021; 71 (3): 209-249. https://doi.org/10.3322/caac.21660
3. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012; 15; 118 (22): 5463-5472. https://doi.org/10.1002/cncr.27581
4. Liu Z, Li M, Jiang Z, Wang X. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Translational Oncology 2018; 11 (2): 311-329. https://doi.org/10.1016/j. tranon.2018.01.011
5. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 2015; 27; 4 (9): e985930. https://doi.org/10. 4161/2162402X.2014.985930
6. Loi S, Sirtaine N, Piette F, Salgado R, Viale G et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node- positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02- 98. Journal of Clinical Oncology 2013; 31 (7): 860-867. https:// doi.org/10.1200/JCO.2011.41.0902
7. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 2008; 26: 677-704. https://doi.org/10.1146/ annurev.immunol.26.021607.090331
8. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. Journal of Experimental Medicine 2009; 206 (13): 3015-3029. https://doi.org/10.1084/ jem.20090847
9. Li Z, Dong P, Ren M, Song Y, Qian X et al. PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer 2016; 7 (7): 784-793. https://doi.org/10.7150/ jca.14549
10. Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open 2017; 2 (2): e000150. https://doi.org/10.1136/ esmoopen-2016-000150
11. Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A et al. Understanding LAG-3 Signaling. International Journal of Molecular Sciences 2021; 22 (10): 5282. https://doi. org/10.3390/ijms22105282
12. Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Seminars in Immunology 2019; 42: 101305. https://doi.org/10.1016/j.smim.2019.101305
13. Burugu S, Gao D, Leung S, Chia SK, Nielsen TO. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Annals of Oncology 2017; 28 (12): 2977-2984. https://doi.org/10.1093/ annonc/mdx557
14. Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C et al. An immune stratification reveals a subset of PD-1/LAG-3 double- positive triple- negative breast cancers. Breast Cancer Research 2016; 18 (1): 121. https://doi.org/10.1186/s13058- 016-0783-4
15. Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G et al. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology 2017; 8: 1412. https://doi.org/10.3389/fimmu.2017.01412
16. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncology 2019; 5 (1): 74-82. https://doi.org/10.1001/jamaoncol.2018.4224
17. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine 2018; 379 (22): 2108-2121. https://doi.org/10.1056/NEJMoa1809615
18. Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E et al. LAG- 3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Research 2003; 63 (10): 2518-2525.
19. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research 2012; 72 (4): 917-927. https://doi. org/10.1158/0008-5472.CAN-11-1620
20. Stovgaard ES, Kümler I, List-Jensen K, Roslind A, Christensen IJ et al. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. Applied Immunohistochemistry & Molecular Morphology 2022; 30 (1): 62-71. https://doi.org/10.1097/PAI.0000000000000954
21. Wang Y, Dong T, Xuan Q, Zhao H, Qin L et al. Lymphocyte- Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer. Journal of Breast Cancer 2018; 21 (2): 124-133. https://doi.org/10.4048/ jbc.2018.21.2.124
22. Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes & Cancer 2018; 9 (5-6): 176-189. https://doi.org/10.18632/ genesandcancer.180
23. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clinical Cancer Research 2009; 15 (19): 6225- 6231. https://doi.org/10.1158/1078-0432.CCR-09-0068
24. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H et al. KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. The New England Journal of Medicine 2022; 386 (6): 556-567. https://doi.org/10.1056/NEJMoa2112651
25. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation 2011; 121 (7): 2750-2767. https://doi.org/10.1172/JCI45014
26. Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Scientific Reports 2019; 9 (1): 19107. https://doi. org/10.1038/s41598-019-55710-w

APA	tahtaci g, GÜNEL N, Sadioğlu A, Akyurek N, Boz O (2023). LAG-3 expression in tumor microenvironment of triple-negative breast cancer. , 142 - 148. 10.55730/1300-0144.5567
Chicago	tahtaci gozde,GÜNEL NAZAN,Sadioğlu Aysu,Akyurek Nalan,Boz Oğulcan LAG-3 expression in tumor microenvironment of triple-negative breast cancer. (2023): 142 - 148. 10.55730/1300-0144.5567
MLA	tahtaci gozde,GÜNEL NAZAN,Sadioğlu Aysu,Akyurek Nalan,Boz Oğulcan LAG-3 expression in tumor microenvironment of triple-negative breast cancer. , 2023, ss.142 - 148. 10.55730/1300-0144.5567
AMA	tahtaci g,GÜNEL N,Sadioğlu A,Akyurek N,Boz O LAG-3 expression in tumor microenvironment of triple-negative breast cancer. . 2023; 142 - 148. 10.55730/1300-0144.5567
Vancouver	tahtaci g,GÜNEL N,Sadioğlu A,Akyurek N,Boz O LAG-3 expression in tumor microenvironment of triple-negative breast cancer. . 2023; 142 - 148. 10.55730/1300-0144.5567
IEEE	tahtaci g,GÜNEL N,Sadioğlu A,Akyurek N,Boz O "LAG-3 expression in tumor microenvironment of triple-negative breast cancer." , ss.142 - 148, 2023. 10.55730/1300-0144.5567
ISNAD	tahtaci, gozde vd. "LAG-3 expression in tumor microenvironment of triple-negative breast cancer". (2023), 142-148. https://doi.org/10.55730/1300-0144.5567

APA	tahtaci g, GÜNEL N, Sadioğlu A, Akyurek N, Boz O (2023). LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences, 53(1), 142 - 148. 10.55730/1300-0144.5567
Chicago	tahtaci gozde,GÜNEL NAZAN,Sadioğlu Aysu,Akyurek Nalan,Boz Oğulcan LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences 53, no.1 (2023): 142 - 148. 10.55730/1300-0144.5567
MLA	tahtaci gozde,GÜNEL NAZAN,Sadioğlu Aysu,Akyurek Nalan,Boz Oğulcan LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences, vol.53, no.1, 2023, ss.142 - 148. 10.55730/1300-0144.5567
AMA	tahtaci g,GÜNEL N,Sadioğlu A,Akyurek N,Boz O LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences. 2023; 53(1): 142 - 148. 10.55730/1300-0144.5567
Vancouver	tahtaci g,GÜNEL N,Sadioğlu A,Akyurek N,Boz O LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turkish Journal of Medical Sciences. 2023; 53(1): 142 - 148. 10.55730/1300-0144.5567
IEEE	tahtaci g,GÜNEL N,Sadioğlu A,Akyurek N,Boz O "LAG-3 expression in tumor microenvironment of triple-negative breast cancer." Turkish Journal of Medical Sciences, 53, ss.142 - 148, 2023. 10.55730/1300-0144.5567
ISNAD	tahtaci, gozde vd. "LAG-3 expression in tumor microenvironment of triple-negative breast cancer". Turkish Journal of Medical Sciences 53/1 (2023), 142-148. https://doi.org/10.55730/1300-0144.5567